AR085155A1 - Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestos - Google Patents
Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestosInfo
- Publication number
- AR085155A1 AR085155A1 ARP120100446A ARP120100446A AR085155A1 AR 085155 A1 AR085155 A1 AR 085155A1 AR P120100446 A ARP120100446 A AR P120100446A AR P120100446 A ARP120100446 A AR P120100446A AR 085155 A1 AR085155 A1 AR 085155A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- pharmaceutical compositions
- processes
- compositions containing
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Composiciones farmacéuticas y compuestos de fórmula (4) y (5), útiles como moduladores de la protein quinasa.Reivindicación 1: Un proceso para preparar un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, en la que: X1 es H, Br, Cl o F; X2 es H, Br, Cl o F; n1 es 1 - 2; y n2 es 1 - 2; comprendiendo el proceso: poner en contacto el compuesto de fórmula (2) con el reactivo de fórmula (3) para producir el compuesto de la formula (1).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161441520P | 2011-02-10 | 2011-02-10 | |
| US201161441527P | 2011-02-10 | 2011-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085155A1 true AR085155A1 (es) | 2013-09-11 |
Family
ID=45615082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100446A AR085155A1 (es) | 2011-02-10 | 2012-02-10 | Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestos |
Country Status (21)
| Country | Link |
|---|---|
| US (11) | US9717720B2 (es) |
| EP (2) | EP2673262B1 (es) |
| JP (2) | JP2014505109A (es) |
| KR (7) | KR20210147117A (es) |
| CN (1) | CN103459373B (es) |
| AR (1) | AR085155A1 (es) |
| AU (6) | AU2012214322B2 (es) |
| BR (1) | BR112013020362A2 (es) |
| CA (1) | CA2826751C (es) |
| DK (1) | DK2673262T3 (es) |
| EA (1) | EA033513B1 (es) |
| ES (1) | ES2905571T3 (es) |
| GE (3) | GEP20217235B (es) |
| HU (1) | HUE057574T2 (es) |
| IL (1) | IL227848B (es) |
| MX (2) | MX390726B (es) |
| PL (1) | PL2673262T3 (es) |
| PT (1) | PT2673262T (es) |
| TW (2) | TWI640509B (es) |
| WO (1) | WO2012109510A1 (es) |
| ZA (1) | ZA201306072B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA038195B1 (ru) | 2009-01-16 | 2021-07-22 | Экселиксис, Инк. | Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени |
| WO2012009722A1 (en) | 2010-07-16 | 2012-01-19 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| DK2621481T4 (da) | 2010-09-27 | 2023-01-09 | Exelixis Inc | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
| TWI640509B (zh) | 2011-02-10 | 2018-11-11 | 艾克塞里克斯公司 | 製造喹啉化合物之方法及包含該化合物之醫藥組合物 |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| TWI610918B (zh) | 2011-05-02 | 2018-01-11 | 艾克塞里克斯公司 | 治療癌症及骨癌疼痛之方法 |
| GEP201606523B (en) | 2011-09-22 | 2016-08-10 | Exelixis Inc | Method for treating osteoporosis |
| EP2768796B1 (en) | 2011-10-20 | 2019-11-20 | Exelixis, Inc. | Process for preparing quinoline derivatives |
| WO2013166296A1 (en) | 2012-05-02 | 2013-11-07 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| CN103664776B (zh) * | 2012-09-26 | 2016-05-04 | 正大天晴药业集团股份有限公司 | 一种酪氨酸激酶抑制剂及其中间体的制备方法 |
| CA2907334C (en) | 2013-03-15 | 2021-12-07 | Exelixis, Inc. | Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| US11564915B2 (en) | 2013-04-04 | 2023-01-31 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| CN103751140A (zh) * | 2014-01-15 | 2014-04-30 | 青岛市肿瘤医院 | 一种Cabozantinib分散片及其制备方法 |
| AU2015218236B2 (en) | 2014-02-14 | 2019-06-13 | Exelixis, Inc. | Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use |
| US10159666B2 (en) | 2014-03-17 | 2018-12-25 | Exelixis, Inc. | Dosing of cabozantinib formulations |
| CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
| CN106715397B (zh) | 2014-07-31 | 2021-07-23 | 埃克塞里艾克西斯公司 | 制备氟-18标记的卡博替尼及其类似物的方法 |
| BR112017002318A2 (pt) | 2014-08-05 | 2018-07-17 | Exelixis, Inc. | combinações de fármacos para tratar mieloma múltiplo. |
| CN105503717A (zh) * | 2014-09-24 | 2016-04-20 | 江苏奥赛康药业股份有限公司 | 一种苹果酸卡博替尼化合物及其药物组合物 |
| CN109069499A (zh) | 2016-04-15 | 2018-12-21 | 埃克塞里艾克西斯公司 | 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法 |
| JP2019529476A (ja) | 2016-09-27 | 2019-10-17 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｎ−（４−（６，７−ジメトキシキノリン−４−イルオキシ）フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドを用いた尿路上皮癌及び他の尿生殖器悪性腫瘍の治療方法 |
| IL270780B2 (en) * | 2017-05-26 | 2025-04-01 | Exelixis Inc | Crystalline solid forms of salts of N–{4–[(7,6–dimethoxyquinolin–4–yl)oxy]phenyl}–N'–(4–fluorophenyl)cyclopropane–1,1–dicarboxamide, processes for preparation and methods of use |
| GEAP202415420A (en) | 2018-01-26 | 2024-12-25 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| CN120305263A (zh) | 2018-06-15 | 2025-07-15 | 汉达癌症医药责任有限公司 | 卡博替尼的盐类于制备治疗癌症的剂型的用途 |
| CA3126721A1 (en) | 2019-01-25 | 2020-07-30 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| EP4622961A1 (en) | 2022-11-25 | 2025-10-01 | Synthon B.V. | A process for preparation of cabozantinib or tivozanib |
| AU2024215796A1 (en) | 2023-01-31 | 2025-05-15 | Handa Oncology, Llc | Improved cabozantinib compositions and methods of use |
| CN116333534B (zh) * | 2023-04-04 | 2023-11-17 | 清远拜克家居有限公司 | 一种耐老化木质板材用水性涂料及其制备方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5358941A (en) | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
| DE69733752T2 (de) | 1996-05-20 | 2006-06-01 | G.D. Searle Llc, Chicago | Arzneimittel enthaltend oxaprozin-natriumsalz,-kaliumsalz, oder-tris(hydroxymethyl)aminomethansalz |
| CA2361057C (en) * | 1999-01-22 | 2010-04-06 | Kazuo Kubo | Quinoline derivatives and quinazoline derivatives |
| WO2003074497A1 (en) | 2002-03-01 | 2003-09-12 | Pintex Pharmaceutical, Inc. | Pin1-modulating compounds and methods of use thereof |
| JP3763414B2 (ja) | 2002-10-21 | 2006-04-05 | 麒麟麦酒株式会社 | Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形 |
| CA2744997A1 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| TWI347940B (en) | 2003-11-07 | 2011-09-01 | Novartis Ag | Methods for synthesizing quinolinone compounds |
| KR100839554B1 (ko) | 2003-12-25 | 2008-06-20 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 염 또는 그 용매화물의결정 및 이들의 제조 방법 |
| WO2006014325A2 (en) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
| JP2008537748A (ja) | 2005-04-06 | 2008-09-25 | エクセリクシス、インコーポレイテッド | ｃ−Ｍｅｔモジュレーター及び使用方法 |
| TWI392681B (zh) | 2006-04-06 | 2013-04-11 | Daiichi Sankyo Co Ltd | 高純度普拉格雷及其酸加成鹽之製法 |
| US20080004273A1 (en) | 2006-05-30 | 2008-01-03 | Stephane Raeppel | Inhibitors of protein tyrosine kinase activity |
| ES2703723T3 (es) | 2006-12-14 | 2019-03-12 | Exelixis Inc | Métodos para usar inhibidores de MEK |
| UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| WO2009136663A1 (en) * | 2008-05-08 | 2009-11-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
| AR075084A1 (es) | 2008-09-26 | 2011-03-09 | Smithkline Beecham Corp | Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes |
| CA2743416A1 (en) | 2008-11-13 | 2010-05-20 | Exelixis Inc. | Methods of preparing quinoline derivatives |
| EP2367795A1 (en) | 2008-12-04 | 2011-09-28 | Exelixis, Inc. | Methods of preparing quinoline derivatives |
| EA038195B1 (ru) * | 2009-01-16 | 2021-07-22 | Экселиксис, Инк. | Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени |
| WO2010113183A2 (en) | 2009-04-03 | 2010-10-07 | Msn Laboratories Limited | Process for the preparation of 1-[[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl]sulfonyl] pyrrolidine and its pharmaceutically acceptable salts |
| EP2454238A1 (en) | 2009-07-17 | 2012-05-23 | Exelixis, Inc. | Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| EP2475390A4 (en) | 2009-09-09 | 2014-01-01 | Quintiles Transnat Corp | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS |
| EP2545038A1 (en) | 2010-03-12 | 2013-01-16 | Exelixis, Inc. | Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| US20140186407A9 (en) | 2010-07-16 | 2014-07-03 | Exelixis Inc. | C-Met Modulator Pharmaceutical Compositions |
| WO2012009722A1 (en) | 2010-07-16 | 2012-01-19 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| JP2013540759A (ja) | 2010-09-27 | 2013-11-07 | エクセリクシス， インク． | 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬 |
| DK2621481T4 (da) | 2010-09-27 | 2023-01-09 | Exelixis Inc | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
| CN103391773A (zh) | 2010-09-27 | 2013-11-13 | 埃克塞里艾克西斯公司 | 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂 |
| JP2013543011A (ja) | 2010-11-22 | 2013-11-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド | 癌の治療法 |
| TWI640509B (zh) | 2011-02-10 | 2018-11-11 | 艾克塞里克斯公司 | 製造喹啉化合物之方法及包含該化合物之醫藥組合物 |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| TWI610918B (zh) | 2011-05-02 | 2018-01-11 | 艾克塞里克斯公司 | 治療癌症及骨癌疼痛之方法 |
| TW201306842A (zh) | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法 |
| GEP201606523B (en) | 2011-09-22 | 2016-08-10 | Exelixis Inc | Method for treating osteoporosis |
| EP2768796B1 (en) | 2011-10-20 | 2019-11-20 | Exelixis, Inc. | Process for preparing quinoline derivatives |
| EP2776033A1 (en) | 2011-11-08 | 2014-09-17 | Exelixis, Inc. | Dual inhibitor of met and vegf for treating cancer |
| WO2013166296A1 (en) | 2012-05-02 | 2013-11-07 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| EP2892532B1 (en) | 2012-09-07 | 2019-02-13 | Exelixis, Inc. | Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma |
| US20140221372A1 (en) | 2013-02-06 | 2014-08-07 | GlaxoSmithKline Intellectual Property (NO 2.) Limited | Method of administration and treatment |
| CA2907334C (en) | 2013-03-15 | 2021-12-07 | Exelixis, Inc. | Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| KR20150138268A (ko) | 2013-04-04 | 2015-12-09 | 엑셀리시스, 인코포레이티드 | 암을 치료하기 위한 약물 병용요법 |
| US10159666B2 (en) | 2014-03-17 | 2018-12-25 | Exelixis, Inc. | Dosing of cabozantinib formulations |
| AU2018279834B2 (en) * | 2017-06-09 | 2024-05-23 | Exelixis, Inc. | Liquid dosage forms to treat cancer |
-
2012
- 2012-02-10 TW TW105117666A patent/TWI640509B/zh active
- 2012-02-10 DK DK12704492.3T patent/DK2673262T3/da active
- 2012-02-10 HU HUE12704492A patent/HUE057574T2/hu unknown
- 2012-02-10 MX MX2017012701A patent/MX390726B/es unknown
- 2012-02-10 GE GEAP201213221A patent/GEP20217235B/en unknown
- 2012-02-10 KR KR1020217038913A patent/KR20210147117A/ko not_active Ceased
- 2012-02-10 JP JP2013553580A patent/JP2014505109A/ja active Pending
- 2012-02-10 KR KR1020217002055A patent/KR20210010671A/ko not_active Ceased
- 2012-02-10 KR KR1020137023174A patent/KR102030447B1/ko active Active
- 2012-02-10 AU AU2012214322A patent/AU2012214322B2/en active Active
- 2012-02-10 WO PCT/US2012/024591 patent/WO2012109510A1/en not_active Ceased
- 2012-02-10 GE GEAP202413811A patent/GEAP202413811A/en unknown
- 2012-02-10 MX MX2013009116A patent/MX2013009116A/es unknown
- 2012-02-10 CA CA2826751A patent/CA2826751C/en active Active
- 2012-02-10 BR BR112013020362A patent/BR112013020362A2/pt not_active Application Discontinuation
- 2012-02-10 EP EP12704492.3A patent/EP2673262B1/en not_active Revoked
- 2012-02-10 KR KR1020247039112A patent/KR20240170977A/ko active Pending
- 2012-02-10 PT PT127044923T patent/PT2673262T/pt unknown
- 2012-02-10 CN CN201280017723.1A patent/CN103459373B/zh active Active
- 2012-02-10 KR KR1020237038819A patent/KR20230158644A/ko not_active Ceased
- 2012-02-10 US US13/984,559 patent/US9717720B2/en active Active
- 2012-02-10 EA EA201391145A patent/EA033513B1/ru not_active IP Right Cessation
- 2012-02-10 PL PL12704492T patent/PL2673262T3/pl unknown
- 2012-02-10 TW TW101104440A patent/TW201309650A/zh unknown
- 2012-02-10 ES ES12704492T patent/ES2905571T3/es active Active
- 2012-02-10 KR KR1020207007647A patent/KR20200031711A/ko not_active Ceased
- 2012-02-10 KR KR1020197012256A patent/KR20190049907A/ko not_active Ceased
- 2012-02-10 GE GEAP201213811A patent/GEP20247677B/en unknown
- 2012-02-10 EP EP21205831.7A patent/EP4019498A1/en active Pending
- 2012-02-10 AR ARP120100446A patent/AR085155A1/es not_active Application Discontinuation
-
2013
- 2013-08-07 IL IL227848A patent/IL227848B/en active IP Right Grant
- 2013-08-13 ZA ZA2013/06072A patent/ZA201306072B/en unknown
-
2016
- 2016-05-10 JP JP2016094411A patent/JP6513598B2/ja active Active
- 2016-11-10 US US15/348,716 patent/US10123999B2/en active Active
-
2017
- 2017-07-14 AU AU2017204877A patent/AU2017204877A1/en not_active Abandoned
-
2018
- 2018-10-04 US US16/151,653 patent/US10543206B2/en active Active
-
2019
- 2019-05-29 AU AU2019203745A patent/AU2019203745B2/en active Active
- 2019-12-06 US US16/706,323 patent/US20200108059A1/en not_active Abandoned
-
2020
- 2020-11-19 AU AU2020273307A patent/AU2020273307A1/en not_active Abandoned
-
2021
- 2021-01-19 US US17/152,394 patent/US20210154185A1/en not_active Abandoned
- 2021-02-08 US US17/170,275 patent/US11298349B2/en active Active
- 2021-10-08 US US17/497,201 patent/US20220023284A1/en not_active Abandoned
-
2022
- 2022-02-24 US US17/679,634 patent/US20220175757A1/en not_active Abandoned
- 2022-10-06 AU AU2022246429A patent/AU2022246429A1/en not_active Abandoned
-
2024
- 2024-02-08 US US18/436,836 patent/US12128039B2/en active Active
- 2024-07-31 AU AU2024205231A patent/AU2024205231A1/en active Pending
- 2024-09-27 US US18/899,774 patent/US20250017916A1/en not_active Abandoned
-
2025
- 2025-05-08 US US19/202,778 patent/US20250262200A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390726B (es) | Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen tales compuestos. | |
| CY1119731T1 (el) | Διαδικασια για την παρασκευη παραγωγων χολικου οξεος | |
| EA201300388A1 (ru) | Соединения замещенного бензамида | |
| CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| EA201590953A1 (ru) | Пирролидиновые модуляторы gpr40 | |
| ECSP14013239A (es) | Composiciones farmacéuticas | |
| EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
| MX2016006336A (es) | Compuestos pirazolopirimidina. | |
| EA201492023A1 (ru) | Регуляторы пути комплемента и их применение | |
| EA201401292A3 (ru) | Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их | |
| MX362383B (es) | Moduladores de acido oxabiciclo[2.2.2] gpr120. | |
| EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
| GT201300123A (es) | Sal(es) de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-(2,3-d)-pirimidin-6-carboxilico y procesos para su elaboracion | |
| EA201491149A1 (ru) | Пиразолопиридиновые производные, способы их получения и их терапевтическое применение | |
| EA201590954A1 (ru) | Дигидропиразольные модуляторы gpr40 | |
| EA201600121A1 (ru) | Новые индольные и пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| CL2012002082A1 (es) | Proceso para la preparacion de lacosamida, por hidroximetilación; compuestos intermediarios. | |
| NI201200195A (es) | Procedimiento de preparación de la sal de l - arginina de perindoprilo | |
| DOP2014000177A (es) | Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2 | |
| ECSP13012548A (es) | Inhibidores de oxadiazol de la producción de leucotrienos. | |
| MY164880A (en) | Process for the preparation of isoxazolyl-methoxy-nicotinic acids | |
| CL2018000151A1 (es) | Procesos mejorados para la preparación de compuestos de 1-aril-5-alquil pirazol (divisional de solicitud 201402825) | |
| SG10201901578UA (en) | Processes for the preparation of pyrimidinylcyclopentane compounds | |
| EA201301136A3 (ru) | Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей | |
| SA112330994B1 (ar) | عملية جديدة لتخليق إيفابردين وأملاح الإضافة الخاصة به مع حمض مقبول صيدلانياً |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |